clinical trial · NCT04565236
A Post Approval Commitment Study to Gain More Information on How Safe and Effective KOVALTRY is in Chinese Children, Adolescents /Adults With Severe Hemophilia A
Bayer·phase4·completed·n = 45
Hemophilia ARecombinant Factor VIII (Kovaltry, BAY81-8973) Treatment Group 1Recombinant Factor VIII (Kovaltry, BAY81-8973) Treatment Group 2Recombinant Factor VIII (Kovaltry, BAY81-8973) Treatment Group 3
brief summary
The goal of this study is to gather more information on safety and efficacy of Kovaltry for the prevention and treatment of bleeds in Chinese children, adolescents/adults with severe hemophilia A. In addition, pharmacokinetic parameters of Kovaltry will be assessed in a subset of patients.
started
Sep 22, 2020
primary completion
Mar 15, 2024
completion
Mar 15, 2024
last updated
Apr 18, 2025
official title
A Post Approval Commitment Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of KOVALTRY in Chinese Children, Adolescents /Adults With Severe Hemophilia A
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol